MBA JD - Kala Pharmaceuticals Chief Officer
| KALA Stock | USD 6.55 0.12 1.87% |
Executive
MBA JD is Chief Officer of Kala Pharmaceuticals
| Age | 45 |
| Address | 1167 Massachusetts Avenue, Arlington, MA, United States, 02476 |
| Phone | 781 996 5252 |
| Web | https://www.kalarx.com |
Kala Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4025) % which means that it has lost $0.4025 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.4811) %, meaning that it created substantial loss on money invested by shareholders. Kala Pharmaceuticals' management efficiency ratios could be used to measure how well Kala Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.79. In addition to that, Return On Capital Employed is expected to decline to -0.86. At present, Kala Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 98.6 M, whereas Total Assets are forecasted to decline to about 53.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Blair Jackson | Alkermes Plc | 51 | |
| Eric Benevich | Neurocrine Biosciences | 59 | |
| Matthew Abernethy | Neurocrine Biosciences | 44 | |
| Jackie Klecker | Lifecore Biomedical | N/A | |
| Darin Lippoldt | Neurocrine Biosciences | 58 | |
| Jaclyn Jaffe | Journey Medical Corp | N/A | |
| Gene Esq | Shuttle Pharmaceuticals | N/A | |
| Dong Yu | Dynavax Technologies | N/A | |
| Julie Cooke | Neurocrine Biosciences | 58 | |
| Donn Casale | Dynavax Technologies | N/A | |
| Todd Lopeman | Dynavax Technologies | N/A | |
| Craig MD | Alkermes Plc | 56 | |
| Willie MD | Intracellular Th | N/A | |
| William CPA | Organogenesis Holdings | N/A | |
| Darin Esq | Neurocrine Biosciences | 58 | |
| Alycia Torres | Biofrontera | N/A | |
| Huang CFA | China Pharma Holdings | N/A | |
| Suresh MD | Intracellular Th | 55 | |
| Robert MD | Dynavax Technologies | 70 | |
| Joseph Benesch | Journey Medical Corp | 57 | |
| David Boyer | Neurocrine Biosciences | 45 | |
Management Performance
| Return On Equity | -2.48 | ||||
| Return On Asset | -0.4 |
Kala Pharmaceuticals Leadership Team
Elected by the shareholders, the Kala Pharmaceuticals' board of directors comprises two types of representatives: Kala Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kala. The board's role is to monitor Kala Pharmaceuticals' management team and ensure that shareholders' interests are well served. Kala Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kala Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO Treasurer | ||
| Michele LaRussa, Senior Vice President - Regulatory Affairs and Quality Assurance | ||
| Jill Steier, Executive Communications | ||
| Carl Rennie, Executive Management | ||
| MBA JD, Chief Officer | ||
| Todd Bazemore, President COO | ||
| Kim Brazzell, Chief Medical Officer | ||
| Justin Hanes, Founder Board | ||
| Josiah Craver, Senior Controller | ||
| Mark Iwicki, Chairman of the Board and Presidentident, CEO | ||
| Eric Trachtenberg, General Counsel, Corporate Secretary | ||
| Mary CPA, CFO Treasurer | ||
| Francis MD, Chief Advisor | ||
| Vincent Kosewski, Senior Vice President - Manufacturing and Supply Chain Management | ||
| James Patnoe, Commercial Access |
Kala Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kala Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.48 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 17.48 M | ||||
| Shares Outstanding | 4.61 M | ||||
| Shares Owned By Insiders | 5.14 % | ||||
| Shares Owned By Institutions | 48.13 % | ||||
| Number Of Shares Shorted | 37.47 K | ||||
| Price To Earning | (0.52) X | ||||
| Price To Book | 4.32 X | ||||
| Price To Sales | 1.16 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kala Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kala Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kala Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kala Pharmaceuticals Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. If investors know Kala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.67) | Quarterly Revenue Growth (1.00) | Return On Assets (0.40) | Return On Equity (2.48) |
The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kala Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kala Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.